Ochre Bio is a biotechnology company that develops and builds a deep phenotyping platform to rejuvenate transplant livers.
Ochre Bio has raised $30.0M in total funding. The most recent round was Series A. The last funding was announced in October 2022.
Ochre Bio's investors include Khosla Ventures, Y Combinator, Apollo Health Ventures, Acequia Capital (AceCap), BACKED VC.
Ochre Bio is headquartered in Oxford, United Kingdom.
Ochre Bio is a biotechnology company that develops and builds a deep phenotyping platform to rejuvenate transplant livers.
Ochre Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ochre Bio — Funding & Investors." VCBacked, October 10, 2022, https://www.vcbacked.co/company/ochre-bio. Accessed September 30, 2026.
VCBacked. (2022). Ochre Bio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/ochre-bio
{{cite web |title=Ochre Bio — Funding & Investors |url=https://www.vcbacked.co/company/ochre-bio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated